Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer ...

Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal ...

Pfizer PFE has committed significant resources toward the development of treatments in the fields of oncology, metabolic ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Whichever one you choose, you'll need patience before you can see solid returns.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

New BCMA-targeted bispecific antibody addresses critical unmet need in India, offering deep and durable responses for heavily ...

(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...

Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's recent announcement about the lung cancer drug that has ...